Analysts Offer Insights on Healthcare Companies: Atricure (NASDAQ: ATRC) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRCResearch Report) and BioMarin Pharmaceutical Inc. (BMRNResearch Report) with bullish sentiments.

Atricure (ATRC)

In a report released today, Suraj Kalia from Northland Securities maintained a Buy rating on Atricure, with a price target of $30. The company’s shares closed yesterday at $28.17.

According to TipRanks.com, Kalia is a 5-star analyst with an average return of 10.3% and a 56.2% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Varex Imaging Corporation, and Strata Skin Sciences Inc.

Atricure has an analyst consensus of Strong Buy, with a price target consensus of $37, representing a 31.3% upside. In a report issued on April 12, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $37 price target.

See today’s analyst top recommended stocks >>

BioMarin Pharmaceutical Inc. (BMRN)

Wedbush analyst Liana Moussatos reiterated a Buy rating on BioMarin Pharmaceutical Inc. today and set a price target of $128. The company’s shares closed yesterday at $85.31.

According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -8.9% and a 32.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.

BioMarin Pharmaceutical Inc. has an analyst consensus of Strong Buy, with a price target consensus of $115.08, representing a 34.9% upside. In a report issued on April 18, Piper Jaffray also maintained a Buy rating on the stock with a $120 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.